Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
MD vs DBVT vs THC vs ALKS vs HCA
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Medical - Care Facilities
Biotechnology
Medical - Care Facilities
MD vs DBVT vs THC vs ALKS vs HCA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology | Medical - Care Facilities | Biotechnology | Medical - Care Facilities |
| Market Cap | $1.90B | $1712.35T | $17.01B | $5.90B | $95.95B |
| Revenue (TTM) | $1.93B | $0.00 | $21.45B | $1.56B | $75.60B |
| Net Income (TTM) | $174M | $-168M | $1.70B | $153M | $6.78B |
| Gross Margin | 25.5% | — | 42.8% | 65.4% | 41.5% |
| Operating Margin | 11.9% | — | 16.1% | 12.3% | 15.8% |
| Forward P/E | 10.3x | — | 10.9x | 24.8x | 14.2x |
| Total Debt | $660M | $22M | $13.17B | $70M | $50.20B |
| Cash & Equiv. | $375M | $194M | $2.88B | $1.12B | $1.04B |
MD vs DBVT vs THC vs ALKS vs HCA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Pediatrix Medical G… (MD) | 100 | 147.6 | +47.6% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
| Tenet Healthcare Co… (THC) | 100 | 892.1 | +792.1% |
| Alkermes plc (ALKS) | 100 | 216.4 | +116.4% |
| HCA Healthcare, Inc. (HCA) | 100 | 401.5 | +301.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MD vs DBVT vs THC vs ALKS vs HCA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, MD doesn't own a clear edge in any measured category.
DBVT is the #2 pick in this set and the best alternative if momentum is your priority.
- +110.4% vs ALKS's +16.5%
THC ranks third and is worth considering specifically for long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- Beta 0.71, current ratio 1.76x
- Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs DBVT's 0.3%
HCA carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Rev growth 7.1%, EPS growth 29.0%, 3Y rev CAGR 7.9%
- 7.1% revenue growth vs DBVT's -100.0%
- Beta 0.29 vs DBVT's 1.26
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.1% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67 | |
| Quality / Margins | 9.8% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.29 vs DBVT's 1.26 | |
| Dividends | 0.7% yield; 5-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +110.4% vs ALKS's +16.5% | |
| Efficiency (ROA) | 11.3% ROA vs DBVT's -89.0% |
MD vs DBVT vs THC vs ALKS vs HCA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
MD vs DBVT vs THC vs ALKS vs HCA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 2 of 6 categories
ALKS leads 1 • HCA leads 1 • MD leads 0 • DBVT leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA and DBVT operate at a comparable scale, with $75.6B and $0 in trailing revenue. Profitability is closely matched — net margins range from 9.8% (ALKS) to 7.9% (THC). On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.9B | $0 | $21.5B | $1.6B | $75.6B |
| EBITDAEarnings before interest/tax | $252M | -$112M | $4.3B | $212M | $15.5B |
| Net IncomeAfter-tax profit | $174M | -$168M | $1.7B | $153M | $6.8B |
| Free Cash FlowCash after capex | $238M | -$151M | $3.3B | $392M | $7.7B |
| Gross MarginGross profit ÷ Revenue | +25.5% | — | +42.8% | +65.4% | +41.5% |
| Operating MarginEBIT ÷ Revenue | +11.9% | — | +16.1% | +12.3% | +15.8% |
| Net MarginNet income ÷ Revenue | +9.0% | — | +7.9% | +9.8% | +9.0% |
| FCF MarginFCF ÷ Revenue | +12.3% | — | +15.6% | +25.1% | +10.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.9% | — | +2.8% | +28.2% | +6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +50.0% | +91.5% | +87.6% | -4.1% | +44.6% |
Valuation Metrics
THC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 11.8x trailing earnings, MD trades at a 52% valuation discount to ALKS's 24.8x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.9B | $1712.35T | $17.0B | $5.9B | $95.9B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $1712.35T | $27.3B | $4.9B | $145.1B |
| Trailing P/EPrice ÷ TTM EPS | 11.82x | -0.76x | 12.53x | 24.76x | 15.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 10.26x | — | 10.94x | — | 14.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.38x | — | 0.72x |
| EV / EBITDAEnterprise value multiple | 8.66x | — | 6.34x | 17.25x | 9.37x |
| Price / SalesMarket cap ÷ Revenue | 1.00x | — | 0.80x | 4.00x | 1.27x |
| Price / BookPrice ÷ Book value/share | 2.26x | 0.66x | 1.97x | 3.28x | — |
| Price / FCFMarket cap ÷ FCF | 7.54x | — | 6.72x | 12.28x | 12.47x |
Profitability & Efficiency
Evenly matched — ALKS and HCA each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
MD delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), MD scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.1% | -130.2% | +19.6% | +8.8% | — |
| ROA (TTM)Return on assets | +8.1% | -89.0% | +5.7% | +5.4% | +11.3% |
| ROICReturn on invested capital | +14.8% | — | +13.2% | +18.9% | +19.9% |
| ROCEReturn on capital employed | +13.2% | -145.7% | +13.8% | +14.2% | +27.0% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 4 | 7 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.76x | 0.13x | 1.47x | 0.04x | — |
| Net DebtTotal debt minus cash | $285M | -$172M | $10.3B | -$1.0B | $49.2B |
| Cash & Equiv.Liquid assets | $375M | $194M | $2.9B | $1.1B | $1.0B |
| Total DebtShort + long-term debt | $660M | $22M | $13.2B | $70M | $50.2B |
| Interest CoverageEBIT ÷ Interest expense | 20.20x | -189.82x | 4.28x | 32.30x | 5.37x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +7.7% | +4.9% | -2.7% | +25.3% | -8.6% |
| 1-Year ReturnPast 12 months | +59.8% | +110.4% | +27.4% | +16.5% | +19.7% |
| 3-Year ReturnCumulative with dividends | +67.0% | +19.7% | +178.5% | +14.5% | +57.4% |
| 5-Year ReturnCumulative with dividends | -28.6% | -69.1% | +190.4% | +60.9% | +109.7% |
| 10-Year ReturnCumulative with dividends | -67.1% | -87.0% | +523.4% | -11.0% | +450.5% |
| CAGR (3Y)Annualised 3-year return | +18.6% | +6.2% | +40.7% | +4.6% | +16.3% |
Risk & Volatility
Evenly matched — ALKS and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.73x | 1.26x | 0.71x | 1.06x | 0.29x |
| 52-Week HighHighest price in past year | $24.99 | $26.18 | $247.21 | $36.60 | $556.52 |
| 52-Week LowLowest price in past year | $11.84 | $7.53 | $146.60 | $25.17 | $330.00 |
| % of 52W HighCurrent price vs 52-week peak | +91.8% | +76.3% | +78.5% | +96.7% | +77.1% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 48.1 | 52.9 | 60.2 | 30.8 |
| Avg Volume (50D)Average daily shares traded | 772K | 252K | 1.2M | 2.3M | 1000K |
Analyst Outlook
HCA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: MD as "Hold", DBVT as "Buy", THC as "Buy", ALKS as "Buy", HCA as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -3.0% for MD (target: $22). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $22.25 | $46.33 | $268.00 | $44.00 | $527.45 |
| # AnalystsCovering analysts | 33 | 15 | 32 | 28 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +0.7% |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | 0 | 5 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.94 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.6% | 0.0% | +8.4% | +0.5% | +10.5% |
THC leads in 2 of 6 categories (Valuation Metrics, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
MD vs DBVT vs THC vs ALKS vs HCA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MD or DBVT or THC or ALKS or HCA a better buy right now?
For growth investors, HCA Healthcare, Inc.
(HCA) is the stronger pick with 7. 1% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Pediatrix Medical Group, Inc. (MD) offers the better valuation at 11. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MD or DBVT or THC or ALKS or HCA?
On trailing P/E, Pediatrix Medical Group, Inc.
(MD) is the cheapest at 11. 8x versus Alkermes plc at 24. 8x. On forward P/E, Pediatrix Medical Group, Inc. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — MD or DBVT or THC or ALKS or HCA?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: THC returned +523. 4% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MD or DBVT or THC or ALKS or HCA?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 339% more volatile than HCA relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MD or DBVT or THC or ALKS or HCA?
By revenue growth (latest reported year), HCA Healthcare, Inc.
(HCA) is pulling ahead at 7. 1% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Pediatrix Medical Group, Inc. grew EPS 263. 0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MD or DBVT or THC or ALKS or HCA?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MD or DBVT or THC or ALKS or HCA more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pediatrix Medical Group, Inc. (MD) trades at 10. 3x forward P/E versus 14. 2x for HCA Healthcare, Inc. — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — MD or DBVT or THC or ALKS or HCA?
In this comparison, HCA (0.
7% yield) pays a dividend. MD, DBVT, THC, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is MD or DBVT or THC or ALKS or HCA better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MD and DBVT and THC and ALKS and HCA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MD is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; THC is a mid-cap deep-value stock; ALKS is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock. HCA pays a dividend while MD, DBVT, THC, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.